Study details
Enrolling now
Assess Fibrin in Brains With AD/ADRD
Massachusetts General Hospital
NCT IDNCT05336695ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
30
Study length
about 4.5 years
Ages
55–90
Locations
1 site in MA
About this study
This trial is testing a new imaging test called 64Cu-FBP8-PET to measure fibrin levels in the brains of people with Alzheimer's Disease or Dementia of Alzheimer Type. The goal is to see if there are differences in fibrin levels based on how far along the disease is.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 64Cu-FBP8
- 2.Undergo PET/MR Imaging
PhasePhase 1/Phase 2
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Procedures
imaging
Devices
diagnostic
Body systems
Neurology